Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 10,510 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 12 Years to 17 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
Interventions: ATLCAR.CD30 cells; Biological
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 3 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2039
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Advanced Cancer, Anorexia, Weight Loss, Insomnia
Interventions: Mirtazapine, Placebo; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Autosomal Dominant Polycystic Kidney Disease
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 15 Years to 40 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetic Macular Edema
Interventions: Faricimab; Drug
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Modesto, California • Sacramento, California • Oak Forest, Illinois + 7 more

Conditions: Knee Osteoarthritis, Traumatic Arthritis of Knee, Avascular Necrosis, Degenerative Joint Disease of Knee, Rheumatoid Arthritis of Knee, Correction of Functional Deformity
Interventions: Primary Knee implants; Device
Lead sponsor: MicroPort Orthopedics Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 1
States / cities: Saginaw, Michigan

Conditions: Healthy Participants
Interventions: STAR-0310, Placebo; Drug
Lead sponsor: Astria Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ulcerative Colitis
Interventions: Vedolizumab, Tofacitinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 36
States / cities: Dothan, Alabama • Sun City, Arizona • Los Angeles, California + 32 more

Conditions: Hematopoietic Cell Transplantation (HCT)
Interventions: Mindful Music Listening (MML); Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypogonadism, Male, End Stage Renal Disease (ESRD), Kidney Transplant
Interventions: Testosterone Replacement Therapy; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hidradenitis Suppurativa
Interventions: Ruxolitinib Cream, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 573 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 67
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 57 more

Conditions: Tumor Genomic Profiling
Interventions: survey, semi-structured interview; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 495 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1
Interventions: [203Pb]VMT-α-NET, SPECT/CT; Drug · Device
Lead sponsor: Yusuf Menda; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Solid Tumor
Interventions: IDE397, Sacituzumab govitecan; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 15
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Duarte, California + 11 more

Conditions: Asthma, Asthma in Children, Pediatric Asthma, Chronic Respiratory Disease
Interventions: AeviceMD; Device
Lead sponsor: Irina Dralyuk; Other
Eligibility: 3 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: COVID-19 Testing Behaviors
Interventions: COVID-19 rapid test-to-treat, Standard COVID19 education control arm; Behavioral
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years to 120 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Radiation Induced Fibrosis
Interventions: Losartan 25 milligram capsule, Placebo; Drug
Lead sponsor: Shaw Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Edwards, Colorado

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: 8 weeks of home based use.; Device
Lead sponsor: Michigan State University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Type 2 Diabetes
Interventions: Time restricted feeding; Behavioral
Lead sponsor: OhioHealth; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Glioblastoma Multiforme
Interventions: Dichloroacetate (DCA), Genotype; Drug · Genetic
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • Winston-Salem, North Carolina

Conditions: HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Lupus Erythematosus, Systemic
Interventions: Cenerimod, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more

Conditions: Post Traumatic Stress Disorder
Interventions: Bupivacaine, Saline; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: The Focus of This Study is to Identify How Different Approaches to Mammography Communication Affect Skepticism Toward Mammography Evidence
Interventions: Harm/benefit language vs. outcomes that can happen, Breast cancer survivability information, No intervention; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 39 Years to 49 Years · Female only
Enrollment: 1,900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Exploring Adherence Monitoring in Sickle Cell Disease

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Effects of Mirtazapine on Appetite in Advanced Cancer Patients

A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD

Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

Post Market Clinical Follow-Up Study for EVOLUTION® BIOFOAM® Tibia and EVOLUTION® CS/CR Porous Femur

A Study of STAR-0310 in Healthy Adult Participants

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Music During Allogeneic Stem Cell Transplant Hospitalization

TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

Cancer Patients Decision Making and Family Communication About Secondary Findings From Tumor Genomic Profiling

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

AeviceMD for Pediatric Asthma Management

COVID-19 Rapid Test-to-Treat With African American Churches (Faithful Response II)

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

Efficacy of the Apollo System for Children With ADHD

Application of Time Restriction Feeding in Patients With Type 2 Diabetes Mellitus

Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)

Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Effects of Stellate Ganglion Block in Post-traumatic Stress Disorder

Evaluating Mammography Communication Approaches